The role of antimicrobial therapy stewardship in intensive care service | CMAC

The role of antimicrobial therapy stewardship in intensive care service

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):132-140

​ Rudnov V.A., Kolotova G.B., Bagin V.A., Nevskaya N.N., Belsky D.V., Ivanova N.A., Gayfutdinov E.A.
10.36488/cmac.2018.2.132-140
antibiotic resistance intensive care unit antimicrobial therapy stewardship
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(2):132-140

Abstract

An analysis of current trends in the prevalence of nosocomial infections, their etiology and antibiotic resistance in pathogens was performed. Social and economic consequences of antimicrobial resistance as well as a medical community’s response were shown. A role of the AMRmap Internet resource in monitoring antibiotic resistance in Russia was demonstrated. The results of our own approaches to the antimicrobial therapy stewardship in the intensive care service of a large hospital were evaluated.

Vladimir A. Rudnov

Ural State Medical University, Yekaterinburg, Russia
City Clinical Hospital №40, Yekaterinburg, Russia

Kolotova G.B.

City Clinical Hospital №40, Yekaterinburg, Russia
Ural State Medical University, Yekaterinburg, Russia

Vladimir A. Bagin

City Clinical Hospital №40, Yekaterinburg, Russia
Ural State Medical University, Yekaterinburg, Russia

Nevskaya N.N.

City Clinical Hospital №40, Yekaterinburg, Russia

Belsky D.V.

City Clinical Hospital №40, Yekaterinburg, Russia
Ural State Medical University, Yekaterinburg, Russia

Ivanova N.A.

City Clinical Hospital №40, Yekaterinburg, Russia

Gayfutdinov E.A.

City Clinical Hospital №40, Yekaterinburg, Russia

  • 1. Zhiganova L.P. Use of antibiotics in agricultural production in the United States and the European Community. Available at: www.portal-slovo.ru/impressionism/36424.php. Accessed 12.10.2014. Russian.
  • 2. Larsson D., Pedro C., Paxeus N. Effluent from drug manufactures contains extremely levels of pharmaceuticals. J Hazard Mater. 2007;148:751-755.
  • 3. Gothwal R., Shashidhar T. Antibiotic pollution in the environment: a review. Clean – Soil, Air, Water. 2015;43(4):479-489.
  • 4. Kummerer K. Antibiotics in aquatic environment – a review, part I. Chemosphere. 2009;75:417-434.
  • 5. Fatta-Kassinos D., Meric S., Nikolau A. Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. Anal Bioanal Chem. 2011;399(1):251-275.
  • 6. Michael I., Rizzo C., Mc Andell C., et al. Urban wastewater treatment plants as hotspots for release of antibiotic in the environment: a review. Water Res. 2013;47:957-995.
  • 7. Fedosenko S.V., Ogorodova L.M., Deev I.A., et al. Analysis of Antibiotic Resistance Genes in Intestinal Microbiota in Patients with Chronic Obstructive Pulmonary Disease. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2015;17(2):157-166. Russian.
  • 8. Kozlov R.S., Golub A.V., Dekhnich A.V., Sukhorukova M.V., SMART Study Group. Antimicrobial Resistance of Gram-negative Microorganisms Causing Complicated Intra-abdominal Infections in Russia. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2015;17(3):227-234. Russian.
  • 9. Barber S., Sutherland N. O’Neil review into antibiotic resistance. CDP 2017⁄0074 6.03.2017. Available at: http://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf.
  • 10. Esen S., Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicenter 1-day point prevalence study. Scand J Infect Dis. 2004;36(2):144-148.
  • 11. Richards M.J., Edwards J., Culver D., Gaynes R. Nosocomial infections in medical intensive care units in The United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27(5):887-892.
  • 12. Rudnov V.А., Belsky D.V., Dekhnich А.V., and the RIORITA Study Group Infections in Russian ICUs: Results of the Nationwide Multicenter Study. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2011;13(4):294-303. Russian.
  • 13. Sukhorukova М.V., Edelstein М.V., Skleenova Е.Yu., et al. Antimicrobial Resistance of Nosocomial Enterobacteriaceae Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 20112012. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16(4):254-265. Russian.
  • 14. Sukhorukova М.V., Edelstein М.V., Skleenova Е.Yu., et al. Antimicrobial Resistance of Nosocomial Acinetobacter spp. Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 20112012. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16(4):266-272. Russian.
  • 15. Sukhorukova М.V., Edelstein М.V., Skleenova Е.Yu., et al. Antimicrobial Resistance of Nosocomial Pseudomonas aeruginosa Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 20112012. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16(4):273-279. Russian.
  • 16. Sukhorukova М.V., Edelstein М.V., Skleenova Е.Yu., et al. Antimicrobial Resistance of Nosocomial Staphylococcus aureus Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 2011-2012. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16(4):280-286. Russian.
  • 17. Yakovlev S.V., Suvorova M.P., Beloborodov V.B., et al. Multicentre Study of the Prevalence and Clinical Value of Hospital-Acquired Infections in Emergency Hospitals of Russia: ERGINI Study Team. Antibiotiki i himioterapija. 2016;61(5-6):32-42. Russian.
  • 18. Reshedko G.K., Ryabkova E.L., Kretchikova O.I., et al. Antimicrobial Resistance Patterns of Gram-negative Nosocomial Pathogens in Russian ICUs. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2008;10(2):96-112. Russian.
  • 19. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 20. CDDEP. Resistance Map. Antibiotic Resistance. Available at: http://resistancemap.cddep.org/AntibioticResistance.php. Accessed: 12.12.2015.
  • 21. ECDC. European Antimicrobial Resistance Surveillance Network [EARS-Net]. Available at: http://ecdc.Europa.eu/en/healthtopics/antimicrobialresistance–and-consumption/antimicrobialresistance/EARS-Net/Pages/EARS-Net.aspx. Accessed: 11.07.2016.
  • 22. O’Neil J. Antimicrobial Resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrobial Res. 2014;1-16.
  • 23. Spielberg D., Guidos R., Gilbert D., et al. The epidemic of antibioticresistant infection: a call to action for the medical community from Infection Diseases Society of America. Clin Infect Dis. 2008;46:155-164.
  • 24. Combating antimicrobial resistance, including antibiotic resistance. WHO Executive Board 134 session. January 20, 2014.
  • 25. ECDC/EMEA. Technical report. The bacterial challenge: time to react. September 2009. Available at: www.ecdc.europa.eu/en/publication/Publications/0909_TER_Thebacterial_challenge_timetoreact.pdf. Accessed Oct 31, 2013.
  • 26. Davies S. Annual report department of health. Press release, March 12, 2013.
  • 27. Department of health and prime minister’s office. Prime minister warns of global threat of antibiotic resistance. July 2, 2014.
  • 28. Implementation of the global action plan on antimicrobial resistance. WHO GAP AMR Newsletter №6 March 1-15, 2016. Available at: www.who.int/antimicrobial-resistance/news/amr-newsletter-no61mar2016.pdf?ua=1.
  • 29. De Waele J., Akova M., Antonelli M., et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2018;44(2):189-196.
  • 30. Barlam T., Cosgrove S., Abbo L., et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Disease Society of America and Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77.
  • 31. Pollak L., van Santen K., Weiner L., et al. Antibiotic stewardship programs in U.S. acute care Hospitals: findings from the 2014 National Healthcare Network (NHSN) annual hospital survey. Clin Infect Dis. 2016;63:446-449.
  • 32. Honda H.,Ohmagari N., Tokuda Y., et al. Antimicrobial stewardship in inpatient settings in the Asia Pacific region: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:119-126.
  • 33. Anderson D., Jenkins T., Evans S. The role of stewardship in addressing antibacterial resistance: stewardship and infection control committee of the antibacterial resistance leadership group. Clin Infect Dis. 2017;64(S1):36-40.
  • 34. Avri T., Levcovich A., D’Ad-El D., et al. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. BMJ. 2010;340:241-248.
  • 35. Tagami T., Matsui H., Fushimi K., et al. Prophylactic antibiotics may improve outcome in patients with severe burns requiring mechanical ventilation: propensity score analysis of Japanese Nationwide database. Clin Infect Dis. 2016;62(1):60-66.
  • 36. Hoff W., Bonadies J., Cachecho R., et al. East practice management guidelines work group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011;70(3):751-754.
  • 37. Colodner R., Rock W., Chazan B., et al. Risk factors for the development of Extended-Spectrum Beta-Lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163-167.
  • 38. Carmeli Y., Troillet N., Eliopoulos G., et al. Emergence of AntibioticResistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents. Antimicrob Agents Chemother. 1999;43:1379-1382.
  • 39. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: A Cohort Study during an Epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
  • 40. Chuchalin A.G., Sinopalnikov A.I., Kozlov R.S., et al. Clinical Guidelines on Diagnosis, Treatment and Prophylaxis of Severe Community-Acquired Pneumonia in Adults. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2015;17(2):84-126. Russian.
  • 41. Rhodes A., Evans L., Alhazzani W., et al. Surviving Sepsis Campaign: International Guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;3(3):304-377.
  • 42. Daikos G., Tsaousi S.,Tzouvelekis L., et al. Carbapenemase-produicing Klebsiella pneumoniae bloodstream infection: lowering mortality by antibiotic combination schemees and role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322-2328.
  • 43. Bassetti M., De Waele J., Eggiman P., et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41(5):776-795.
  • 44. Kollef M., Micek S. Antimicrobial de-escalation: what is in a name? Clin Infect Dis. 2016;62(8):1018-1020.
  • 45. Tabah A., Cotta M., Garnacho-Montero J., et al. A systematic review of the definition, determinants and clinical outcomes of antimicrobial de-escalation in the ICU. Clin Infect Dis. 2016;62(8):1009-1017.
  • 46. Collins V., Marchaim O., Pogue J., et al. Efficacy of ertapenem for treatment of bloodstream infection caused by ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:21732177.
  • 47. Garnacho-Montero J., Gutierrez-Pizarraya A., Escoresca-Ortega A., et al. De-escalation of empirical therapy associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40(1):32-40.
  • 48. Leon M., Bechis C., Baumstarck K., et al. De-escalation versus continuation of empirical antimicrobial teratment in severe sepsis: multicenter non-blinded randomized trial. Intensive Care Med. 2014;40(10):1399-1408.
  • 49. Bochorishvili V.G. Sepsisology with the basics of infectious pathology. Mecniereba. Tbilisi., 1988. 806 p. Russian.
  • 50. Leon M., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730-737.
  • 51. Falcey A., Murata Y., Walsh E. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007;167:354-360.
  • 52. Morill H., Pogue J., Kaye K., LaPlante K. Treatment option for carbapenem-resistant Enterobacteriaceae infection. Open Forum Infect Dis. 2015;2(2):ofv050.
  • 53. Mensa J., Barberan J., Soriano A., et al. Antibiotic selection in the treatment of acute invasive infection by P. aeruginosa: guidelines by Spanish Society Chemotherapy. Rev Esp Quimiother. 2018;31(1):78100.
  • 54. Гусаров В.Г. Стратегия мониторинга и управления антибиотикорезистентностью при лечении инфекций у хирургических больных в многопрофильном стационаре: автореф. дис… д-ра мед наук: 14.01.17. Гусаров Виталий Геннадьевич. М., 2017. 43 с.
  • 55. Zamyatin M., Gusarov V., Petrova N., et al. Results of antimicrobial stewardship programme implementation in multidisciplinary hospital. ICU management and practice. 2018;18(2). Available at: https://healthmanagement.org/c/icu/issuearticle/results-of-antimicrobialstewardship-programme-implementation-in-multidisciplinaryhospital.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared